Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA 2025 AML Highlights
24 June 2025 | Virtual Meeting
Post-EHA 2025 AML Highlights
Featuring presentations & discussions on selected AML abstracts from the 30th Congress of the European Hematology Association (EHA).
Chair: Naval Daver | Moderators: Charles Craddock & Eunice Wang
The Post-EHA 2025 AML Highlights webinar has been supported by Sumitomo Pharmaceuticals (Silver Sponsorship). Supporters have had no influence over the production of this activity.
Genomic classification and precision risk stratification in AML
Targeting FLT3-mutated AML: New combinations and long-term outcomes
Novel treatment approaches for NPM1 and KMT2A-mutated AML
AML and beyond – advances in core-binding factor AML, transplant and BPDCN
Advances with low-intensity induction strategies
Session1: Genomic classification and precision risk stratification in AML
Development and independent validation of unsupervised genomic classification of patients with acute myeloid leukemia using hierarchical dirichlet mixture models. A HARMONY ALLIANCE study
Amin Turki Ruhr-University Hospital Bochum & University Hospital Essen, Germany
Risk stratification of newly diagnosed acute myeloid leukemia treated with venetoclax in combination with intensive chemotherapy
Wei-Ying Jen The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion
Session 2: Targeting FLT3-mutated AML: New combinations and long-term outcomes
The combination of a FLT3-ITD, NPM1MUT and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: analysis from the QUANTUM-FIRST trial
Mark Levis Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
Phase I/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML
Musa Yilmaz University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion
Session 3: Novel treatment approaches for NPM1 and KMT2A-mutated AML
Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-M or KMT2A-R acute myeloid leukemia (AML): Updated Phase ll a/b results from KOMET-007
Harry Erba Duke Cancer Institute, Durham, NC, United States
RP2D determination of bleximenib in combination with VEN+AZA: Phase llb study in ND & R/R AML with KMT2A/NPM1 alterations
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
Azacitidine, venetoclax, and revumenib for newly diagnosed older adults with acute myeloid leukemia (AML) and NPM1 mutation or KMT2A rearrangement: Updated results from the BEAT AML consortium
Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States
Panel discussion
Session 4: AML and beyond – advances in core-binding factor AML, transplant and BPDCN
Phase lll study of intensive chemotherapy with or without dasatinib in patients with core-binding factor acute myeloid leukemia - final analysis of the AMLSG 21-13 TRIAL
Katharina Götze Technical University of Munich, Munich, Germany
Efficacy and safety of pivekimab sunirine in patients with BPDCN in the CADENZA study
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in patients with AML: Results of a Phase l/ll clinical trial
Uday Popat The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion
Session 5: Advances with low-intensity induction strategies
All-oral decitabine-cedazuridine (DEC-C) + venetoclax (VEN) IN patients with newly diagnosed acute myeloid leukemia (AML) ineligible for induction chemotherapy: Phase l/ll clinical trial results
Gail Roboz Weill Medical College of Cornell University, New York City, NY, United States
Tuscany study of safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in study participants with newly diagnosed AML ineligible for induction chemotherapy
Gabriel Mannis Stanford University School of Medicine, Stanford, CA, United States
Phase II study of cladribine with low dose cytarabine and venetoclax alternating with azacytidine and venetoclax newly diagnosed acute myeloid leukemia
Tapan Kadia The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion
